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Results: Initially, 65% of subjects received warfadn, but only 49% were on warfarin at 12 
months. Hypertension, CHF, valvular heart disease and a rate control strategy were pre- 
dictors of initial warfarin use; age<55 years, female gender, and history of coronary artery 
or ulcer disease were negative predictors. Predictors of warfarin use at 12 months are 
shown in Table 1. Hypertension, ulcer disease, gender, and physician specialty were not 
predictive. The strongest predictor of warfarin use at 12 months was recurrence of AF. 
Conclusions: Predictors of warfadn use in AF patients include stroke risk factors and 
potential warfarin contraindications. In addition, AF recurrence is a potent predictor for 
warfarin use 12 months after initial diagnosis. 
Table 1. Predictors of warfarin use at 12 months 
Variable Odds ratio (95% CI) P value 
AF recurrence 2.27 (1.51-3.42) 0.0001 
Prior stroke/TIA 2.09 (1.15-3.79) 0.02 
CHF 1.89 (1.25-2.87) 0.003 
Valvular disease 1.78 (1.16-2.66) 0.008 
Age <55 0.49 (0.33-0.74) 0.0008 
1066-106 Compar i son  of  Transesophageal Echocardiography- 
Detected Thromboembolic Risk Markers in Patients 
With Chronic Atrial Fibrillation and Atrial Tachycardia 
According to the SPAF Clinical Risk Stratification: A 
Prospective Study 
Nadia Benyounes, Valdrie Rozenberg, Lydia Djaouti, Charles Smadja, Mohammed 
Khirredine, Ariel Cohen. Saint Antoine University Hospital and Medical School, Paris. 
The thromboembolic (TE) risk of atdal flutter and tachycardias (AFT) has been reported 
as lower than atrial fibrillation (AF). Current guidelines suggest the need for a similar anti- 
coagulant strategy in both groups, This attitude could be balanced by a risk stratification 
using SPAF clinical cdteria and TE echocardiographic markers, 
Objective : We sought to compare the frequency of TE risk markers in patients (Pts) with 
chronic AF and AFT according to the SPAF clinicat criteria for TE dsk stratification. 
Methods : As part of an ongoing prospective study, we evaluated 212 Pts in chronic AF 
and 77 Pts in AFT using transthoracic and transesophagaal echocardiography (TEE). Pts 
were divided into high (n=113 and 43, respectively) and moderate/low (n=99 and 34, 
respectively) SPAF clinical risk groups. The following parameters were evaluated : left 
atdal (LA) and LA appendage (LAA) areas, spontaneous echo contrast (SEC), LAA end 
diastolic emptying velocity (Vel), LA thrombus (Thr) and thoracic aorta atheroma (TAA). 
Results : The main results are summarized in the table 
Chronic AF High Chronic AF Moderate/ AFT High AFT Moderate/ 
risk (n=113) low risk (n=99) risk (n=43) low risk (n=34) 
Mean age 75 ± 11 63.1 _+ 11.5 70.9 + 14.2 63.7 ± 12.9 
(years) 
LA area (cm 2) 24.7 ± 6.3 24.3 ± 6.0 23.7 ± 7.2 22.3 ± 6.9 
LAA area (cm 2) 5.4 + 2.3 5.9 ± 2.6 5.8 ± 2.6 5.4 ± 2.4 
LAA Vel <_25 55 (50.9)* 32 (34.7) 9 (21.9) 8 (25.0) 
cm/s (n,%) 
LA SEC (n,%) 75 (73.5)* 60 (63,8) 18 (45.8) 12 (44.4) 
LAA Thr (n,%) 6 (5.3) 1 (1.0) 2 (4.6) 0 
TAA_> 4 mm 18(17.3) 10(10.4) 10(23.8) 4(13.3) 
(n,%) 
*p< 0.05, high risk AF vs high risk AFT ; ** p< 0.05, moderate/low AF vs moderate/low 
risk AFT. 
Conclusion : LATE risk markers are more frequent in high risk Pts with AE However, 
LA and LAA dilatation and TAA are equally frequent in both high risk Pts. AFT should be 
stratified using the SPAF cdteria, similarly to AF, to help the accurate anticoagulant strat- 
egy. 
1066-119 A Risk Profile for Stroke or Death in Atrial Fibrillation: 
The Framingham Heart Study 
Thomas J. Wane. Joseph M. Massaro, Ralph B. D'Agostino, Daniel Levy, Philip A. Wolf, 
William B. Kannel, Martin G. Larson, Ramachandran S, Vasan, Emelia J, Benjamin, 
Framingham Heart Study, Framingham, Massachusetts. 
BACKGROUND: Individuals with atrial fibrillation (AF) are at increased risk of both 
stroke and death. Risk factors for stroke in AF have been studied, but mainly in subjects 
enrolled in randomized trials. We developed a clinical risk profile, and examined whether 
it could stratify risk among individuals with AF in the community. 
METHODS: We studied 870 subjects (mean age 74, range 55 to 94 years, 46% women) 
from the original and offspring cohorts of the Framingham Heart Study who developed 
AF after 1960, Stepwise Cox proportional hazards models were used to examine clinical 
predictors (obtained from history, physical exam, or ECG) of stroke or death during 5 
years of follow up. Subjects who had a stroke or died within 30 days of AF diagnosis 
were excluded. 
RESULTS: The 5-year event rate was 49%. The following predictors were significant in 
multivariable models: age, systolic blood pressure, smoking, prior myocardial infarction 
or heart failure, and heart murmur. Men in the lowest decile of predicted dsk had a 5-year 
event rate of 9.4%, while those in the highest decile had an event rate of 83.9%. The cor- 
responding values for women were 30.4% and 93.5%. Sex-specific predicted event rates 
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for a representat ive  70 year  old are  shown (Figure). 
CONCLUSION: Using a risk prediction model, it is possible to identify subjects with AF 
who are at particularly high or low risk of stroke or death, 
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1066-120 Embolic Event Rates After Direct Current Csrdioversion 
in Patients With Atrial Fibrillation and Ineffective 
Anticoagulation: Results of the Ludwlgshsfen 
Observational Atrial Fibrillation Study 
Karlheinz Seidl, Monika Rameken. Margit Vater, Harald Schwacke, Andreas Brandt, 
Caroline Bergmeier, Rail Zahn, Jochen Senges, Heart Center, Ludwigshafen, Germany. 
The Ludwigshafen atrial fibrillation (AF) study is a prospective single center observational 
study on an intention to cardiovert basis, including 1269 consecutive unselected patients 
(pts) with AF. Aim of this substudy was to evaluate the embolic event rate in pts with AF 
and ineffective anticoagulation (IA), in whom electrical cardioversion (CV) was intended. 
IA was defined, if warfarin was given, however INR was < 2, or if no anticoagulation was 
performed. Reasons for performing CV in pts with IA were AF of < 48 h, hemodynamic 
instable AF, or contraindication for anticoagulation. After cardioversion an overlap of war- 
farin therapy and intravenous hepadn was given to maintain adequate anticoagulation 
after CV in pts without contraindications for anticoagulation, 
Results: In 193 pts (15%) anticoagulation therapy was ineffective at the time of the 
intended CV. Transesophageal echocardiography (TEE) was performed in 126 pts, in the 
remaining 67 pts transthoracic echo was performed, A thrombus was found in 10 pts 
(7.9%) of the 126 pts with AF and ineffective anticoagulation. In 53 of the 126 pts (42%) 
TEE revealed spontaneous echo contrast. The grade of spontaneous echo contrast was 
mild in 74%, moderate in 19% and severe in 9%. In 150 of the 196 pts (78%) CV was 
performed, in the remaining 43 pts no CV was performed. In 2 of 150 pts (1.3%) with AF 
and IA a transient ischemic attack occurred in the first 4 weeks after CV. In both pts TEE 
was performed before CV, none of the pts had evidence of left atdal thrombus. In none of 
the 43 pts without CV a thromboembolic omplication occurred. In comparison the rate of 
thromboembolic omplications in the first 4 weeks after CV was 0.8 % (9/1076 pts) in pts 
with AF and effective anticoagulation at least 3 weeks prior to CV. 
Conclusion: 1) In our AF outpatient clinic 15% of the pts with AF had ineffective antico- 
agulation prior to CV. 2) The rate of embolic events in the first 4 weeks after the intended 
CV was 1.3 in pts with ineffective anticoagulation compared to 0.8 in pts with effective 
anticoagulation. 
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1067-107 Changes  in R-R Intervals During Ventricular 
Tachyarrhythmia Storms in Patients With Implantable 
Cardioverter-Defibrillator 
Xiaohong Zhou, Vinod Sharma, Jodi L. KoehIer, Paul J. DeGroot, Walter H. Olson, 
Medtronic, Inc, Minneapolis, Minnesota. 
BACKGROUND: Ventricular tachyarrhythmia (VTNF) storms, defined as greater than or 
equal to 3 episodes within 24 hours, have been reported in patients with implantable car- 
dioverter-defibrillator (ICD). The study objective was to determine whether predisposition 
to VTNF storms could be assessed from changes in episode related cardiac cycle 
lengths. METHODS: ICD patients (n=220) with coronary artery disease were followed for 
6.9±3.6 months post-implant. Stored electrograms were retrospectively reviewed and all 
true VTNF episodes, each of which was successfully terminated, were identified. Two 
types of changes in mean R-R interval (R-R) were calculated: (1) Delta-RR1, {[(mean R- 
R immediately prior to an episode)-(baseline mean R-R)]/(baseline mean R-R)}*100%, 
and (2) Delta-RR2, ([(mean R-R immediately after an episode)-(mean R-R immediately 
prior to an episode)]/(mean R-R immediately prior to an episode)}*100%. Baseline mean 
R-R was obtained at office visit and the mean R-Rs immediately prior to and immediately 
after an episode were obtained from ICD electrograms (excluding premature contrac- 
tion). RESULTS: There were a total of 629 episodes in 72 patients. Forty-one patients 
had all discrete episodes (total 91 episodes, group 1) without storms. Thirty-one patients 
experienced at least one storm and had a total of 538 episodes (group 2). Of 538 epi- 
sodes in group 2, 405 episodes (75%, group 2a) occurred in 57 storms and the remaining 
133 episodes were discrete (25%, group 2b). Each VTNF storm consisted of 7.1±5.7 
episodes (median = 5). The Delta-RR1 was -10.7±23.6% for group 1 and -27.3±15.4% 
